Tarsus Pharmaceuticals, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Tarsus is a late clinical-stage biopharmaceutical company developing drug candidates, primarily for ophthalmic conditions. It had no approved products and no product-sales revenue.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Total revenue | $33.4 million | None |
| Operating expenses | $22.7 million | $2.1 million |
| Operating income (loss) | $10.7 million | $(2.1) million |
| Net income (loss) | $10.4 million; $0.47 diluted EPS | $(2.0) million; $(0.74) diluted EPS |
| Operating cash flow | $(11.8) million | $(2.0) million |
| Cash and cash equivalents at quarter-end | $156.2 million | $168.1 million at December 31, 2020 |
| Total liabilities | $10.7 million | $6.0 million at December 31, 2020 |
Q1 revenue and reported profit primarily reflect the China out-license of TP-03, not product sales. The company recognized $33.3 million in license fees and $0.1 million in collaboration revenue; the related revenue cost was $1.3 million. Operating and net margins were approximately 32% and 31%, respectively, but are not indicative of product economics given the license-driven revenue. The filing reports no product gross margin. No material debt or credit facility is reported.
Cash, cash equivalents and restricted cash declined by $12.0 million during the quarter. The company received no China out-license cash in Q1 despite recognizing revenue; $25 million was received in April and May 2021. Current assets were $191.5 million and current liabilities were $10.1 million at March 31, 2021.
Material changes versus the prior comparable period
- Revenue moved from zero to $33.4 million following the March 2021 China out-license, producing reported net income versus a prior-year net loss.
- Research and development expense rose $14.7 million to $16.3 million, primarily due to $5.5 million of stock issued to Elanco for lotilaner license rights, a $2.0 million clinical milestone, higher study costs, manufacturing costs and personnel expense.
- General and administrative expense rose $4.6 million to $5.2 million, reflecting personnel, insurance and administrative costs, professional fees, and commercial and market research spending.
- Operating cash use increased to $11.8 million from $2.0 million, partly because of the timing difference between recognized license revenue and subsequent cash receipts.
Outlook, risks and notable items
- China out-license: LianBio received exclusive TP-03 development and commercialization rights in Greater China for Demodex blepharitis and Meibomian Gland Disease, and is responsible for territory costs. Tarsus reported $25 million received after quarter-end and expected additional payments, including a $10 million clinical milestone by June 30, 2021. Further development, regulatory and sales milestones and tiered royalties are contingent on future events and sales.
- Cash outlook: Management estimated that March 31 cash plus anticipated initial China-license proceeds would fund operations into the first half of 2023. This estimate depends on assumptions and milestone achievement. The filing also states that additional capital will be required to fully develop candidates and that financing may not be available on acceptable terms.
- Clinical program: Saturn-1 was fully enrolled by Q1; the company later announced expected topline results in July 2021. Saturn-2 commenced in Q2 2021. Management expected both pivotal trials to support an NDA submission if results were statistically significant and consistent with FDA discussions.
- Pipeline: TP-05’s IND for Lyme disease prevention was accepted in May 2021, with a Phase 1 study anticipated to begin in Q3 2021. TP-04 and additional TP-03 indications remain in development.
- Principal risks: Clinical efficacy and safety, regulatory approval, market acceptance, competition, third-party manufacturing and trial execution, intellectual-property protection, and reliance on future financing and collaboration payments. COVID-19 had not significantly affected operations to date, but future effects on trials and timelines remained uncertain.
- Contingencies and controls: The company reported no material pending litigation or material changes to previously disclosed risk factors. Management concluded disclosure controls were effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether the expected China-license milestones were achieved and received, and how the agreement’s payment terms and revenue-recognition obligations reconcile across the filing.
- Saturn-1 and Saturn-2 results, their effect on the timing and prospects for an NDA, and any regulatory updates.
- Whether spending, cash burn and clinical costs remain consistent with management’s first-half 2023 runway estimate.
- The valuation and vesting conditions of the LianBio warrants, which use significant unobservable assumptions, and the potential future impact of milestone and royalty obligations to licensors.